Type of lung cancer-Non-small cell lung carcinoma (NSCLC) Posts on Medivizor
Navigation Menu

Type of lung cancer-Non-small cell lung carcinoma (NSCLC) Posts on Medivizor

SBRT vs. radiotherapy in patients with inoperable non-small cell lung cancer

Posted by on Mar 5, 2019 in Lung cancer | 0 comments

In a nutshell This study determined whether stereotactic body radiation therapy (SBRT) was more effective than standard radiotherapy in patients with inoperable non-small cell lung cancer. The study found that SBRT led to better survival outcomes for these patients, with minimal side effects. Some background Tumor removal by surgery is the standard of...

Read More

SBRT vs. radiotherapy in patients with inoperable non-small cell lung cancer

Posted by on Mar 5, 2019 in Lung cancer | 0 comments

In a nutshell This study determined whether stereotactic body radiation therapy (SBRT) was more effective than standard radiotherapy in patients with inoperable non-small cell lung cancer. The study found that SBRT led to better survival outcomes for these patients, with minimal side effects. Some background Tumor removal by surgery is the standard of...

Read More

Effects on survival: thermal ablation vs stereotactic radiation therapy for non-small cell lung cancer

Posted by on Jan 20, 2019 in Lung cancer | 0 comments

In a nutshell This article investigated the safety and effectiveness of thermal ablation (TA) compared to stereotactic radiation therapy (SRT) for the treatment of non-small-cell lung cancer (NSCLC). The authors concluded that both thermal ablation and stereotactic radiation are safe and can improve survival of these patients. Some...

Read More

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

Posted by on Jan 12, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if the medication brigatinib (Alunbrig) is better than crizotinib (Xalkori) in treating patients with lung cancer. The study found that survival was significantly longer in patients who were treated with brigatinib compared to those treated with crizotinib. Some background Brigatinib and crizotinib are a...

Read More

Alectinib vs crizotinib in treating brain or spinal cord tumors in patients with non-small cell lung cancer

Posted by on Jan 12, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out which medication is better for treating lung cancer that has spread to the brain or spinal cord, crizotinib (Xalkori) or alectinib (Alecensa). The study found that alectinib worked better than crizotinib for treatment of tumors of the brain and spinal cord. Some background Alectinib and crizotinib are two...

Read More

Adding local therapy to EGFR inhibitor treatment for lung cancer that has spread to the liver

Posted by on Nov 24, 2018 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if adding extra treatment targeted to the liver alongside treatment with EGFR inhibitors helped in patients with lung cancer that had spread to the liver. The study found that adding the extra treatment meant the patients survived longer compared to treatment with EGFR inhibitors alone. Some background...

Read More

Which chemotherapy drugs are better after surgery for patients with NSCLC?

Posted by on Sep 28, 2018 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness of fluorouracil (Adrucil) chemotherapy after surgery in patients with non-small-cell lung cancer (NSCLC). The authors concluded that treatment with fluorouracil resulted in prolonged recurrence-free survival compared to standard chemotherapy regimens. Some background Adjuvant therapy is given in...

Read More

The link between time to disease progression and survival after progression in patients with advanced lung cancer

Posted by on Sep 18, 2018 in Lung cancer | 0 comments

In a nutshell This study looked at a link between time to disease progression and longer survival after progression in patients with advanced BRAF V600E non-small-cell lung cancer. The authors concluded that a longer time to disease progression after treatment was linked to longer survival in these patients.  Some background Some non-small-cell...

Read More